Aprea Therapeutics, Inc. — Form 8-K Summary
Business context and reporting period
Aprea Therapeutics, Inc. filed a Form 8-K dated August 12, 2021, reporting financial results and operational updates for the second quarter ended June 30, 2021. The company is a clinical-stage biotechnology company, and its common stock trades on Nasdaq under the symbol APRE.
Financial and operating metrics
The filing announces that second-quarter financial results were issued in an attached press release, Exhibit 99.1. The provided filing text does not include the underlying revenue, net loss, cash flow, cash balance, research and development expense, general and administrative expense, debt, liquidity runway, or margin figures.
Material changes versus the prior comparable period
The provided text does not contain comparative financial figures or a clear quantification of changes from the prior-year quarter.
Guidance, outlook, risks, and unusual items
- On August 11, 2021, the FDA placed a clinical hold on Aprea’s trial evaluating eprenetapopt in combination with acalabrutinib or with venetoclax and rituximab in lymphoid malignancies.
- One patient with chronic lymphocytic leukemia was receiving eprenetapopt in combination with venetoclax and rituximab. That patient may continue treatment while deriving clinical benefit.
- No additional patients may be enrolled until the clinical hold is resolved.
- Aprea stated that it intends to work with the FDA to address the agency’s questions and seek resolution of the hold as soon as possible.
- The clinical hold creates a material clinical-development, timing, regulatory, and financing risk for the company’s pipeline. The filing does not provide a resolution timeline or quantify the expected financial impact.
Important facts for investors to verify
- Review Exhibit 99.1 for the complete second-quarter financial statements, cash position, operating expenses, loss, and liquidity outlook.
- Review Exhibit 99.2 for the FDA’s clinical-hold details, including the specific questions or deficiencies cited.
- Confirm the duration and impact of the enrollment suspension on trial milestones and regulatory plans.
- Assess whether the clinical hold changes expected cash needs, financing requirements, or the company’s ability to fund operations.